JP7311160B2 - ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物 - Google Patents

ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物 Download PDF

Info

Publication number
JP7311160B2
JP7311160B2 JP2020508983A JP2020508983A JP7311160B2 JP 7311160 B2 JP7311160 B2 JP 7311160B2 JP 2020508983 A JP2020508983 A JP 2020508983A JP 2020508983 A JP2020508983 A JP 2020508983A JP 7311160 B2 JP7311160 B2 JP 7311160B2
Authority
JP
Japan
Prior art keywords
oil
composition
eyelid
dry eye
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508983A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531462A5 (enExample
JP2020531462A (ja
Inventor
ウィットカップ、スコット
オレイニク、オレスト
ガースト、マイク
エイ． シモンズ、ピーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akrivista LLC
Original Assignee
Akrivista LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akrivista LLC filed Critical Akrivista LLC
Publication of JP2020531462A publication Critical patent/JP2020531462A/ja
Publication of JP2020531462A5 publication Critical patent/JP2020531462A5/ja
Application granted granted Critical
Publication of JP7311160B2 publication Critical patent/JP7311160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
JP2020508983A 2017-08-18 2018-08-17 ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物 Active JP7311160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547553P 2017-08-18 2017-08-18
US62/547,553 2017-08-18
PCT/US2018/046918 WO2019036625A1 (en) 2017-08-18 2018-08-17 METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE

Publications (3)

Publication Number Publication Date
JP2020531462A JP2020531462A (ja) 2020-11-05
JP2020531462A5 JP2020531462A5 (enExample) 2021-09-24
JP7311160B2 true JP7311160B2 (ja) 2023-07-19

Family

ID=65363005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508983A Active JP7311160B2 (ja) 2017-08-18 2018-08-17 ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物

Country Status (7)

Country Link
US (2) US11622982B2 (enExample)
EP (1) EP3668474A4 (enExample)
JP (1) JP7311160B2 (enExample)
CN (2) CN111295169A (enExample)
BR (1) BR112020003276A2 (enExample)
CA (1) CA3072494A1 (enExample)
WO (1) WO2019036625A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524892A (ja) 2016-08-19 2019-09-05 アクリビスタ エルエルシーＡｋｒｉｖｉｓｔａ，Ｌｌｃ ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
WO2019036625A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE
TWI833913B (zh) * 2019-02-27 2024-03-01 日商參天製藥股份有限公司 含有迪夸弗索(diquafosol)或其鹽、乙烯系高分子及纖維素系高分子之眼科用組合物
PL3888634T3 (pl) * 2020-03-31 2023-09-11 Oy Finnsusp Ab Preparat oftalmiczny i jego zastosowanie
EP3919047A1 (en) * 2020-06-03 2021-12-08 AZAD Pharma AG Microemulsion for the treatment of dry eye syndrome
ES2916152A1 (es) * 2020-12-28 2022-06-28 Univ Valladolid Compuestos para su uso en la prevencion y/o tratamiento de la inflamacion y el estres oxidativo del segmento anterior del ojo
CN112842936A (zh) * 2021-03-15 2021-05-28 傅博 一种眼部清洁液及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520210A (ja) 2007-02-28 2010-06-10 アーシエックス セラピューティックス， インコーポレイテッド マイボーム腺分泌を正常化するための方法および組成物
US20100174000A1 (en) 2007-05-29 2010-07-08 Octalia Technologies Carrier in the form of oil-in-water emulsion notably intended for ophthalmic or dermocosmetic use
JP2014528452A (ja) 2011-10-06 2014-10-27 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ドライアイ治療用組成物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US4146499A (en) 1976-09-18 1979-03-27 Rosano Henri L Method for preparing microemulsions
US4585656A (en) 1984-08-20 1986-04-29 Rosenthal Harold R Treatment of herpes
CA2052950A1 (en) 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US5527488A (en) * 1992-08-07 1996-06-18 Amway Corporation High viscosity anhydrous makeup remover gel
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US20030086986A1 (en) 1998-08-06 2003-05-08 Bruijn Chris De Ophthalmic, pharmaceutical and other healthcare preparations with naturally occurring plant compounds, extracts and derivatives
US7262224B2 (en) * 1999-11-30 2007-08-28 Hanna Isul Skin Therapy, Inc. Cosmetic rejuvenating and healing product, method of its manufacture and uses thereof
CA2462272A1 (en) 2001-10-11 2003-04-17 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
US6559182B1 (en) 2001-11-07 2003-05-06 Purcell Jojoba International, Llc Method for treatment of enveloped viruses using jojoba oil esters
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
WO2006004577A2 (en) 2004-03-12 2006-01-12 Melbj Holdings, Llc Lubricant for the ocular surface
JP5272307B2 (ja) 2004-07-16 2013-08-28 大正製薬株式会社 水性点眼剤
WO2006073786A2 (en) 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
US9161905B2 (en) 2005-01-12 2015-10-20 Ocular Research Of Boston, Inc. Dry eye treatment
JP2006233398A (ja) 2005-02-23 2006-09-07 Daiwa Kagaku Kogyo Kk アボガド油及びアボガド油不けん化物を処理したことを特徴とする機能化繊維材料および機能化繊維材料の処理方法。
AU2006247136C1 (en) 2005-05-17 2020-01-16 Bausch + Lomb Ireland Limited Compositions and methods for treatment of eye disorders
US8669241B2 (en) 2008-12-02 2014-03-11 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition
CA2764477A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
EP2437762B1 (en) 2009-06-05 2017-08-09 Allergan, Inc. Artificial tears and therapeutic uses
US9119827B2 (en) 2009-06-30 2015-09-01 Lion Corporation Ophthalmic composition
US8909327B1 (en) 2010-06-23 2014-12-09 Allergan, Inc. Instrument and method for diagnosing dry eye in a patient
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
JP6093701B2 (ja) 2011-07-08 2017-03-08 ロート製薬株式会社 眼科用水性組成物
EP2787969B1 (en) 2011-12-07 2021-09-29 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
JP5988855B2 (ja) 2012-06-27 2016-09-07 ロート製薬株式会社 水性眼科組成物
WO2015137357A1 (ja) 2014-03-10 2015-09-17 サラヤ株式会社 ソホロリピッドと生理活性物質と油脂とを含有する組成物およびその製造方法
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
LT3266446T (lt) 2016-07-07 2019-01-25 Laboratorios Salvat, S.A. Oftalmologinė kompozicija, apimanti ricinos aliejų ir vidutinio grandinės ilgio trigliceridą
JP2019524892A (ja) * 2016-08-19 2019-09-05 アクリビスタ エルエルシーＡｋｒｉｖｉｓｔａ，Ｌｌｃ ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
CN106389218A (zh) 2016-10-28 2017-02-15 林振慧 一种眼部凝露
WO2019036625A1 (en) 2017-08-18 2019-02-21 Akrivista, LLC METHODS FOR DIAGNOSING AND TREATING DRY-LIKE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520210A (ja) 2007-02-28 2010-06-10 アーシエックス セラピューティックス， インコーポレイテッド マイボーム腺分泌を正常化するための方法および組成物
US20100174000A1 (en) 2007-05-29 2010-07-08 Octalia Technologies Carrier in the form of oil-in-water emulsion notably intended for ophthalmic or dermocosmetic use
JP2014528452A (ja) 2011-10-06 2014-10-27 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ドライアイ治療用組成物

Also Published As

Publication number Publication date
BR112020003276A2 (pt) 2020-09-01
CN114376961A (zh) 2022-04-22
EP3668474A1 (en) 2020-06-24
CA3072494A1 (en) 2019-02-21
US20200164013A1 (en) 2020-05-28
EP3668474A4 (en) 2021-05-26
CN111295169A (zh) 2020-06-16
WO2019036625A1 (en) 2019-02-21
JP2020531462A (ja) 2020-11-05
US20230233637A1 (en) 2023-07-27
US12220439B2 (en) 2025-02-11
US11622982B2 (en) 2023-04-11

Similar Documents

Publication Publication Date Title
JP7311160B2 (ja) ドライアイ症候群を診断及び処置する方法及びヒトの眼を処置するための組成物
JP2022177281A (ja) ドライアイ症候群を診断及び治療する方法ならびにヒト眼を治療するための組成物
Yeu et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)
Tauber et al. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease
Dogru et al. Pharmacotherapy of dry eye
Benelli Systane® lubricant eye drops in the management of ocular dryness
Yagci et al. The role and treatment of inflammation in dry eye disease
Wagle et al. Utility values associated with vitreous floaters
Goto et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction
Holzchuh et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin
Koh Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes
Al-Saedi et al. Dry eye disease: present challenges in the management and future trends
Labetoulle et al. Efficacy and safety of dual-polymer hydroxypropyl guar-and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study
Yeu et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle
Wei et al. Antioxidant carbon dots nanozyme loaded in thermosensitive in situ hydrogel system for efficient dry eye disease treatment
Fiscella Understanding dry eye disease: a managed care perspective
BR112021011210A2 (pt) Formulações oftálmicas que proporcionam lubrificação ocular durável
Mergen et al. Swabs containing tea tree oil and chamomile oil versus baby shampoo in patients with seborrheic blepharitis: A double-blind randomized clinical trial
CN110013498A (zh) 一种含盐酸奥洛他定的滴眼液及其制备方法
Philip Nanotechnology-based therapeutic strategies for dry eye disease
US20170239307A1 (en) Composition of doxycycline in liposomes for the prevention, improvement and/or treatment of ocular pathologies
HK40073074A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
HK40007121A (en) Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
Mohapatra et al. Emulsion and Emulgel-Based Ophthalmic Drug Delivery Systems
Markoulli Seventh International Conference on the Tear Film & Ocular Surface: Basic Science and Clinical Relevance (Taormina, Sicily, September 2013). Highlights from the Platform Sessions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230629

R150 Certificate of patent or registration of utility model

Ref document number: 7311160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150